Pharmalot… Pharmalittle… Good Morning
Make a commentBy Ed Silverman // January 11th, 2012 // 8:07 am
Rise and shine. Another sunny day is on the way. And, of course, that means we will celebrate with a delicious cup of stimulation. We urge you to join us. After all, what better way to prepare for a busy schedule of meetings and deadlines. To help you along, we have gathered a few items of interest. So dig in and enjoy yourself. Hope your day goes well and stay in touch…
Greek Debt Crisis Dries Up Drug Supply (Bloomberg News)
Novartis Says Gilenya MS Drug Met Study Goal (Bloomberg News)
AstraZeneca Signs Data Deal With IMS Health (Pharma Times)
Hospira CEO Says Problems Are ‘Fixable’ (InPharma Technologist)
Sales Reps Try A Softer Sell (The Wall Street Journal)
CRO Consolidation To Slow: ICON CEO (Outsourcing Pharma)
J&J And Forma Sign Collaboration Worth Up To $700M (InPharm)
J&J Sold Insulin Pumps After Learning Of Defects: FDA (Bloomberg News)
Pfizer CEO Says Lipitor Market Share Is At Expected Levels (Dow Jones)
EDITOR’S NOTE: Please check this post for updates throughout the morning
Leave a Comment
Subscribe
Comments feed for this post only.
Tags
AstraZeneca, Contract Research Organizations, CRO, European Debt Crisis, Forma Therapeutics, Generics, Gilenya, Greece, Hospira, Icon, IMS Health, Insulin, JJ, Johnson & Johnson, Lipitor, MS, Multiple Sclerosis, Novartis, Pfizer, Pharmaceutical Sales Reps, Sales Reps